Kynteles 300mg Injection contains Vedolizumab, a monoclonal antibody used to treat moderate to severe ulcerative colitis and Crohn's disease. By focusing on particular immunological pathways, it reduces inflammation in the stomach.

Brand Name: Kynteles

Composition: Vedolizumab

Mechanism of Action:

Vedolizumab is a monoclonal antibody that attaches itself to the white blood cell surface protein known as α4β7 integrin. The medication inhibits the interaction with MAdCAM-1 (mucosal addressin cell adhesion molecule-1), which is dominantly expressed in the gastrointestinal (GI) tract, by specifically targeting this integrin. By stopping T-cells from migrating into inflammatory gut tissue, this strategy lowers inflammation without compromising systemic immune function.

Uses:

• Ulcerative Colitis
• Crohn's Disease

Dosage and Administration:

Only given by intravenous (IV) infusion. In a facility designed to handle infusion-related reactions, infusion is administered under close medical monitoring.

Side Effects:

• Headache
• Nausea
• Joint pain
• Fever
• Fatigue
• Vomiting
• Throat Pain

Safety Advise:

Lungs  

The safety of Kynteles Injection for individuals with lung issues is uncertain. Kindly speak with your healthcare provider.

Liver  

The safety of Kynteles Injection for individuals with liver issues is uncertain. Kindly speak with your healthcare provider.

Kidney  

The safety of Kynteles Injection for individuals with Kidney issues is uncertain. Kindly speak with your healthcare provider.

 Pregnancy  

Kynteles should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Kynteles while nursing is most likely dangerous. Kindly speak with your healthcare provider. 

Storage:

Kynteles should be kept in the refrigerator between 2°C and 8°C (36°F and 46°F). The formulation may be harmed by freezing, so avoid doing so.

How to use this Medication?

Vedolizumab is given intravenously over 30 minutes every 2–8 weeks initially, then less often as treatment continues. Following the initial IV doses at weeks 0 and 2, it can transition to subcutaneous injection every two weeks.

During or hours after infusion, vedolizumab may cause severe allergic reactions; keep an eye out for signs such as rash, swelling, disorientation, or trouble breathing. Notify your physician or nurse right away if any of these happen.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Baxter India Pvt Ltd

Address: Baxter (India) Private Limited, 2nd Floor, Tower-C, Building No.8, DLF Cyber City, DLF Phase-II, Gurgaon-122 002, Haryana, India

Country of origin: India